Dr Katie Sutton
About
Biography
Katie is a Post-Doctoral Research Fellow at the University of Surrey with a focus on qualitative research in cancer care and patient experience. She has 15 years experience as a cancer nurse, working mainly in chemotherapy. Katie also led a project to implement stratified follow-up at a large Cancer Centre, which fuelled her passion to carry out more research into personalised cancer care. Katie's PhD explored the perceptions and experiences of people with glioblastoma and how nurses can best support them to maintain their wellbeing.
Affiliations and memberships
ResearchResearch interests
Katie is passionate about conducting research into the experiences and perceptions of cancer patients and professionals to help drive improvements in cancer care. Her particular focus is on personalised cancer and living with and beyond cancer.
Research projects
Does Personalised Stratified Follow-Up (PSFU) meet the health and wellbeing needs of people from under-served groups who have completed treatment for breast cancer? (The B-POISED study)Personalised Stratified Follow-Up (PSFU) is an approach to follow-up after cancer treatment which involves patients re-accessing care when they think they need to, rather than attending predetermined clinic appointments. The intended benefits of this approach include a more personalised experience for patients and increased capacity in outpatient clinics.
The aim of this qualitative study is to improve the health and wellbeing of people from under-served groups in England who have completed treatment for breast cancer by exploring whether PSFU meets their needs, and to make recommendations for future development and feasibility testing.
This study is funded by the NIHR RfPB programme (NIHR206333) September 2024-May 2026
The role of Electronic Frailty Index in improving outcomes for newly diagnosed Cancer patients undergoing systemic Chemotherapy treatmentFunded by NIHR RfPB, 2020-2020
Developing and Delivering targeted SARS-CoV-2(COVID-19) health interventions to Black, Asian and Minority Ethnic (BAME) communities living in the UK.Funded by DHSC/UKRI COVID-19 Rapid Response Initiative, 2020
September 2022-May 2023
Research interests
Katie is passionate about conducting research into the experiences and perceptions of cancer patients and professionals to help drive improvements in cancer care. Her particular focus is on personalised cancer and living with and beyond cancer.
Research projects
Personalised Stratified Follow-Up (PSFU) is an approach to follow-up after cancer treatment which involves patients re-accessing care when they think they need to, rather than attending predetermined clinic appointments. The intended benefits of this approach include a more personalised experience for patients and increased capacity in outpatient clinics.
The aim of this qualitative study is to improve the health and wellbeing of people from under-served groups in England who have completed treatment for breast cancer by exploring whether PSFU meets their needs, and to make recommendations for future development and feasibility testing.
This study is funded by the NIHR RfPB programme (NIHR206333) September 2024-May 2026
Funded by NIHR RfPB, 2020-2020
Funded by DHSC/UKRI COVID-19 Rapid Response Initiative, 2020
September 2022-May 2023
Publications
DERM is an AI algorithm for detecting skin cancer. Developed by Skin Analytics, the algorithm analyses images of skin lesions and determines if the lesion is likely to be cancerous. DERM is already being used by some NHS providers, and is integrated with existing skin cancer pathways, triaging patients before being assessed by dermatologists. The Department of Health and Social Care (DHSC) funded deployment and a real-world evaluation of DERM as part of the AI in Health and Care Award. The evaluation aimed to inform future implementation by assessing key domains such as safety, accuracy, effectiveness, value and sustainability. Working as a collaborative Technology Specific Evaluation Team (TSET), Unity Insights and University of Surrey conducted an evaluation of DERM in four NHS sites, across 9,649 patients between February 2022 and April 2023. The resulting evaluation report is presented in full.
12009 Background: Older and frail patients with cancer (Ca) often receive less aggressive treatment and as a result have worse survival. Current methods of assessing fitness (performance status) for intensive treatment such as chemotherapy are inadequate. The complexity of geriatric assessments, lack of training and time pressures in busy clinics, mean that better solutions are needed. A UK initiative - the electronic frailty index (eFI) - is derived from a cumulative deficit frailty model and provides a measure of frailty alongside pre-existing conditions such as issues with mobility, fractures, falls, memory, sight, hearing , anaemia, tremor, diabetes, heart, thyroid, skin, respiratory, cerebrovascular, circulation, social vulnerability, and polypharmacy (36 fields) (Clegg et al). Patients are classified into the following groups: no frailty, mild, moderate or severe frailty. We used the same methodology to investigate whether eFI predicts adverse outcomes of chemotherapy in frail patients with Ca. Methods: The study conducted retrospective data analysis of Ca patients treated with chemotherapy from Public Health England (PHE) Systemic Chemotherapy Dataset (SACT) years 2015-2018. Eligible patients had stage II - III breast Ca, stage III colon Ca or stage IIIB–IV non-small-cell lung Ca (NSCLC). The data from SACT was linked with hospital episodes' statistics (obtained from NHS-Digital) to calculate 30-day SACT mortality, overall survival and hospital admissions. EFI was calculated from the above 35 fields; polypharmacy was not available from NHS-Digital data. Results: The eFI was calculated for 78799 patients: colorectal 17951, lung 22052, and breast 38796. 20388 patients were ≥ 70y. o. and 58411 were < 70y.o. Most patients were fit with an eFI score of 0-69% (54563), 19% (15,295) had mild frailty, 7.7% (6104)- moderate, and 3.6% (2837) had severe frailty. 4.2% (3356) of patients died within 30 days of SACT. For colorectal Ca patients the risk of dying within 30 days of SACT in patients ≥70y.o was twice that of the < 70y.o (OR 2.04 -CI 1.58 - 2.64); patients with mild eFI did not differ- OR: 1.07 (CI 0.78-1.45), moderate frailty: 1.6 (CI 1.1-2.33) and severe frailty: 2.13 (CI 1.34-3.39). In breast Ca patients, 30-day mortality for ≥70y.o. was 6.38 times higher than for < 70y.o (95% CI 4.29-9.49); eFI for mild frailty- OR of 1.45 (95% CI 0.78-2.71), moderate frailty-OR of 3.5 (95%CI 1.82-6.75) and severe frailty 5.73 (95% CI 2.66-12.3). The 30-day mortality in lung cancer in ≥70y.o and < 70y.o did not differ with OR 0.95 (95% CI 0.88-1.03) for ≥70y.o. Patients with mild frailty had OR for 30-day mortality of 1.17 (95% CI 1.07-1.28), moderate frailty-OR of 1.28 (95%CI 1.15-1.44) and severe frailty 1.48 (95% CI 1.28-1.77). Conclusions: The eFI closely predicts poor outcomes from SACT, particularly in early breast and colon cancer, and requires further evaluation in a prospective study.
Background: The COBHAM study involved the production of a culturally appropriate intervention to provide information on protective behaviours for people from Black and Asian populations. The intervention comprises an e-leaflet and a 3.5-minute film disseminated via a link in a text message sent from GP Practices. We conducted a preliminary evaluation of this intervention to explore how people from the relevant communities understand and interpret the intervention's messages. Aim: To share our experiences of collecting sensitive qualitative data during the Covid-19 pandemic through entirely remote means. The aim being to convey lessons learned about navigating discussions on contentious issues with participants who have strongly held beliefs. Methods: Potential participants were highlighted through an online survey, which asked for their phone number should they be happy to be contacted for an interview. A member of the research team then contacted potential participants to discuss recruitment to the trial. If in agreement, Microsoft Teams meetings were arranged. Information sheets and consent forms were sent via email. Consent was video-recorded at the start of the interview by asking participants to read and agree to the statements in the consent form. Results: Collecting data from people specifically related to a protected characteristic (in this case ethnicity) on potentially sensitive issues (such as protective behaviours relating to covid transmission) required a high level of sensitivity and self-awareness, which was fully integrated into data collection planning. The rapid expansion of using video-conferencing software such as Microsoft Teams meant that people were generally familiar with their use. Conducting the interviews remotely facilitated a comfortable and safe forum for discussion.
The intention of this study was to offer an alternative perspective to the quantitative findings of larger randomised controlled trials by using a phenomenological approach to explore the impact on Quality of Life (QoL) for people with brain tumours of entering a research trial involving new anti-cancer agents. Given the subjective nature of the proposed topic, a phenomenological approach was adopted. Sample size was limited to five participants. A semi-structured interview technique was used. Interviews were digitally audio recorded with permission from those involved. In order to guide data analysis for this study, Colaizzi's framework was utilised. As a result of data analysis, two major themes were identified. These were ‘Hope and optimism’ and ‘The therapeutic relationship’. Three minor themes were also found. These were ‘A complex symptom profile’, ‘The importance of non-medical coping strategies’ and ‘Impressions of the QoL tools used’. This phenomenological study has highlighted key themes relating to QoL which are not addressed in some of the widely used assessment tools such as the EORTC QLQ C30 and BN20. They generally focus on health status, and do not capture issues identified in this study as being of significant importance to the QoL of participants such as hope and optimism, and the importance of the therapeutic relationship. They also omit reference to coping and management strategies.